ERBB2 and ductal breast carcinoma in situ: Evidence from previous studies, including DCIS vaccine trials, has demonstrated that targeting a single antigen, such as HER2, can lead to the emergence of antigen-loss variants, ultimately compromising vaccine efficacy (9, 10).